News

Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology Research

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of preclinical data from MP0317 in Cancer Immunology Research, a journal of the...

read more

SECA Workshop Venture Capital

SECA Venture Capital Workshop: Theorie und Praxis des Investierens Venture Capital kompakt, ganzheitlich und von namhaften Referenten erklärt Auf spannende Fragen gibt es Antworten... Auf was beruhen die Erfolgsgeschichten von Yahoo, Amazon, ebay, Adobe, Intel, Cisco Systems und Genentech? Was haben US-Unternehmen wie Google, Facebook mit Schweizer Erfolgsgeschichten wie WeFox, Bexio,...

read more

European Patent Office to Grant TOPADUR’s Patent Application for TOP-N53

Zurich-Schlieren, Switzerland, March 23rd, 2022. TOPADUR Pharma AG, a clinical-stage biopharmaceutical start-up company developing first-in-class drugs for aging diseases, today announced that the European Patent Office (EPO) granted a patent covering its lead investigational drug product, TOP-N53 used for the treatment of chronic wounds. The European patent covers composition of matter for...

read more

Swiss Biotech Day 2024, April 22-23, Congress Center in Basel

Program: https://swissbiotechday.ch/program-2024/ Registration: https://swissbiotechday.ch/registration-2024/ The Swiss Biotech Day is a premier biotechnology conference in Europe, attracting professionals from the global life sciences community. In 2024, it will once again provide a platform for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing. International...

read more